FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520406626> ?p ?o ?g. }

• W1520406626 endingPage "803" @default.
• W1520406626 startingPage "801" @default.
• W1520406626 abstract "Aspirin (acetyl salicylic acid) is a wonder drug – but does it also have a dark side? We are not referring here only to its adverse effects, important as these are. (A recent meta-analysis leads to the conclusion that in otherwise low risk persons, its harms outweigh its cardiovascular benefits [1] occasioning a re-think among the worried well). Rather, we draw attention to a slowly unfolding drama in which it may yet turn out to play the role, at best, of flawed hero, at worst, of infanticidal villain. The mechanism of action of aspirin was a total mystery for the best part of a century following its synthesis in the Bayer laboratories in the nineteenth century, and remains incompletely understood to this day. The breakthrough came with the work of Ferreira, Moncada & Vane, published in 1971, which showed that it inhibits prostaglandin biosynthesis [2]. This was subsequently discovered to occur through enzymic oxidation of arachidonic acid by one or other of two cyclo-oxygenase isoenzymes, COX-1 and COX-2 (Figure 1). More recently it was discovered that, unexpectedly, aspirin also promotes the synthesis of another class of eicosanoid, the anti-inflammatory lipoxins and resolvins, because COX-2 can still generate hydroxy fatty acids even when acetylated by aspirin [3]. These newish members of the eicosanoid family act as ‘stop’ signals in inflammation. They are formed by the action of 5-lipoxygenase on 15-hydroxy fatty acids derived from arachidonate (in the case of lipoxin) or eicosapentaenoate (in the case of resolvin), and act on the same G-protein-coupled receptor as does annexin-A1 [4]. Arachidonic acid can be oxidized enzymically (via COX-1 and COX-2) to cyclic endoperoxide intermediates or non-enzymically to isoprostanes. The intermediates are converted to prostanoids (thromboxanes and prostaglandins) by different isomerase enzymes in different tissues (e.g. thromboxane synthase in platelets, prostacyclin synthase present in endothelium, PGE synthase in stomach). Low dose aspirin (ASA) blocks COX-1 in platelets and is an effective antithrombotic drug, but causes gastrointestinal toxicity via inhibition of gastrointestinal PGE2 biosynthesis. Unlike aspirin, thromboxane receptor antagonists block the actions of all agonists at thromboxane prostanoid (TP) receptors (including endoperoxides and isoprostanes), without inhibiting either PGI2 or PGE2. Drugs (aspirin and TXRA) are shown in red The discoveries of thromboxanes by Bengt Samuelsson and of prostacyclin by John Vane and their associates led to the demonstration by Moncada & Vane that doses of aspirin up to 300 mg day−1 alter the balance between thromboxane A2, which causes platelet aggregation, vasoconstriction and vascular cell proliferation by acting on thromboxane prostanoid (TP) receptors and prostacyclin (PGI2) which has opposing actions through IP receptors [5]. Aspirin is particularly effective in inactivating COX-1 in platelets which are exposed to relatively high drug concentrations in the portal circulation following oral administration, compared with systemic vascular tissue which is exposed to much lower concentrations due to extensive pre-systemic metabolism. Furthermore, healthy humans regenerate COX coupled to PGI2 biosynthesis (presumably in vascular endothelium) within a few hours [6], whereas platelet TXA2 biosynthesis recovers with the generation of new platelets over several days [7], since platelets do not possess nuclei and lack the macromolecular machinery to direct new protein synthesis. Following oral administration aspirin is de-acetylated within a matter of minutes, so when administered once daily lower doses than are needed for anti-inflammatory activity profoundly (>95%) decrease platelet TXA2 biosynthesis while having only a transitory action on PGI2 production, because platelets in the portal circulation are inhibited whereas PGI2 synthesis occurs mainly in vascular cells in the systemic circulation exposed to much lower aspirin concentrations. Randomized trials of low dose aspirin in secondary prevention have demonstrated unequivocal benefit with reductions in stroke and myocardial infarction of approximately 25% [1]. This familiar success story had a paradoxically chilling effect on the development of drugs that work by closely related but distinct mechanisms to that of aspirin. Despite its cost, synthetic prostacyclin (epoprostenol) found commercial success in several niche indications (for example, to inhibit platelet aggregation during haemodialysis when heparins are unsuitable or contra-indicated, and in patients with primary pulmonary hypertension resistant to other treatments [8]), vindicating Vane's championship. By contrast, thromboxane synthase inhibitors (TXSI) and thromboxane receptor antagonists (TXRA) were perceived as too close to aspirin to compete effectively with this inexpensive and effective drug. Their consequent neglect by the industry may yet prove to have been short-sighted. TXRAs block all TP agonists (Figure 1); these include not only TXA2 (which is effectively and selectively depressed by low doses of aspirin as explained above) but also cyclic endoperoxide (PGH2) and several isoprostanes, non-enzymic products of fatty acid oxidation formed under conditions of increased oxidative stress [9, 10] and which are not inhibited by aspirin. Endogenous TP agonists are produced by the vascular endothelium, especially under pathological conditions, causing endothelium-dependent contraction and contributing to endothelial dysfunction, a key factor in atherogenesis [11]. Treatment with a TXRA, but not treatment with aspirin, inhibits atherogenesis in apo-E deficient mice [12], strongly suggesting that TXRAs not only differ qualitatively from aspirin but could also be superior to aspirin in preventing atheroma. In support of this possibility, acute administration of a single dose of a TXRA (S18886, now known as terutroban) to patients treated with low dose aspirin for coronary artery disease improved endothelial function assessed by measuring flow-mediated dilatation (FMD) in the brachial artery [13]. In this issue of the Journal we publish a paper [14] by Pierre-François Lesault and colleagues from the same group as authored the earlier paper [13]. This adds a further important chapter to the story. These authors studied 48 patients with carotid atherosclerosis (identified by high resolution B-mode ultrasonography) and treated with aspirin 300 mg once daily. This is near the top end of the ‘low-dose’ dose regimens, in contrast to the earlier work. Patients were randomly allocated to placebo or to one of three doses of terutroban for 15 days in a double-blind study. FMD was improved by all doses of terutroban both acutely on day 1 (confirming the observations in coronary artery disease patients mentioned above) but also after 2 weeks of chronic treatment, with no hint of tachyphylaxis. The authors discuss several limitations, notably that FMD was measured only at 2 h after dosing (presumed to be near Tmax), hence leaving open the question of persistence of the pharmacodynamic effects at trough of the different doses used. The effect of TXRA alone on FMD also needs to be ascertained. Nevertheless we are surely closing in on an unanswerable case for an efficacy trial of a TXRA employing a clinically relevant endpoint. It would be ironic if the wonders of aspirin (or, to be less fanciful, their impact on the mindset of drug development scientists) turn out to have hobbled the development of a related but uniquely distinct class of drugs. There is no pharmacologically based expectation that TXRAs will have adverse direct gastrointestinal effects (although they must inevitably promote gastrointestinal, cerebral or other forms of bleeding in the presence of other pathologies), so the glittering prize would be a drug that not only inhibits thrombosis (like aspirin) but additionally prevents atherosclerosis without causing gastrotoxicity. The worried well might chirp up at that prospect – now there's a market!" @default.
• W1520406626 created "2016-06-24" @default.
• W1520406626 creator A5021529820 @default.
• W1520406626 date "2011-05-12" @default.
• W1520406626 modified "2023-09-23" @default.
• W1520406626 title "TP receptor antagonists (TXRAs): expensive irrelevance or wonder drugs strangled at birth?" @default.
• W1520406626 cites W1578596840 @default.
• W1520406626 cites W1969016210 @default.
• W1520406626 cites W1972153352 @default.
• W1520406626 cites W1982041605 @default.
• W1520406626 cites W1984927802 @default.
• W1520406626 cites W2014644245 @default.
• W1520406626 cites W2036866147 @default.
• W1520406626 cites W2042963094 @default.
• W1520406626 cites W2051778349 @default.
• W1520406626 cites W2100089051 @default.
• W1520406626 cites W2124939010 @default.
• W1520406626 cites W4232301166 @default.
• W1520406626 doi "https://doi.org/10.1111/j.1365-2125.2011.03985.x" @default.
• W1520406626 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3099365" @default.
• W1520406626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21564159" @default.
• W1520406626 hasPublicationYear "2011" @default.
• W1520406626 type Work @default.
• W1520406626 sameAs 1520406626 @default.
• W1520406626 citedByCount "4" @default.
• W1520406626 countsByYear W15204066262018 @default.
• W1520406626 countsByYear W15204066262019 @default.
• W1520406626 countsByYear W15204066262021 @default.
• W1520406626 countsByYear W15204066262023 @default.
• W1520406626 crossrefType "journal-article" @default.
• W1520406626 hasAuthorship W1520406626A5021529820 @default.
• W1520406626 hasBestOaLocation W15204066262 @default.
• W1520406626 hasConcept C15744967 @default.
• W1520406626 hasConcept C2780573756 @default.
• W1520406626 hasConcept C71924100 @default.
• W1520406626 hasConcept C77805123 @default.
• W1520406626 hasConcept C98274493 @default.
• W1520406626 hasConceptScore W1520406626C15744967 @default.
• W1520406626 hasConceptScore W1520406626C2780573756 @default.
• W1520406626 hasConceptScore W1520406626C71924100 @default.
• W1520406626 hasConceptScore W1520406626C77805123 @default.
• W1520406626 hasConceptScore W1520406626C98274493 @default.
• W1520406626 hasIssue "6" @default.
• W1520406626 hasLocation W15204066261 @default.
• W1520406626 hasLocation W15204066262 @default.
• W1520406626 hasLocation W15204066263 @default.
• W1520406626 hasLocation W15204066264 @default.
• W1520406626 hasOpenAccess W1520406626 @default.
• W1520406626 hasPrimaryLocation W15204066261 @default.
• W1520406626 hasRelatedWork W2022638962 @default.
• W1520406626 hasRelatedWork W2321205926 @default.
• W1520406626 hasRelatedWork W2744547489 @default.
• W1520406626 hasRelatedWork W2748952813 @default.
• W1520406626 hasRelatedWork W2809947118 @default.
• W1520406626 hasRelatedWork W2899084033 @default.
• W1520406626 hasRelatedWork W3031052312 @default.
• W1520406626 hasRelatedWork W3195975068 @default.
• W1520406626 hasRelatedWork W4230963413 @default.
• W1520406626 hasRelatedWork W752583723 @default.
• W1520406626 hasVolume "71" @default.
• W1520406626 isParatext "false" @default.
• W1520406626 isRetracted "false" @default.
• W1520406626 magId "1520406626" @default.
• W1520406626 workType "article" @default.